Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Extension in CML Myeloid Blast Crisis
NCT00171158Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 1999
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of imatinib in chronic myeloid leukemia (CML), sponsored by Novartis. Primary endpoint: Overall Survival at 14 years. Started Jul 1999; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00171158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171158.